Top

International Journal of Colorectal Disease

Published in:

Open Access 01-10-2010 | Original Article

ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer

Authors: Ewa Balcerczak, Mariusz Panczyk, Sylwester Piaskowski, Grażyna Pasz-Walczak, Aleksandra Sałagacka, Marek Mirowski

Published in: International Journal of Colorectal Disease | Issue 10/2010

Abstract

Objective

To analyse the single-nucleotide polymorphisms (SNPs): ABCB1 _1236C>T, ABCB1 _2677G>T/A, ABCB1 _3435C>T and haplotypes in the ABCB1/MDR1 gene, which could contribute to genetic risk of colorectal cancer (CRC). Disease association between the ABCB1/MDR1 genotype, allele, haplotype frequencies and histological features, such as TNM classification, localization of primary carcinoma, grade of malignancy, histological type of tumour, lymphoid infiltration and vessel invasion were estimated. In this study, the potential role of SNPs of the ABCB1/MDR1 gene as a prognostic marker for CRC was analysed.

Materials and methods

Tumour specimens of 95 patients with CRC were studied. Using automated sequencing or PCR-RFLP method, DNA for three common SNPs of ABCB1/MDR1 was extracted and analysed. The results of genotyping and haplotype analysis with histopathological features, grading and clinical staging of neoplasms were correlated.

Results

A statistically significant higher frequency of T₁₂₃₆ allele in T1/T2 (89.7%), M0 groups (81.6%) and I/II clinical staging (82.7%) in comparison with T3/T4 (68.2%), M1 groups (47.4%) and III/IV clinical staging (65.1%) was detected. Furthermore, multivariate analysis according to Cox's proportional hazard model indicated that the T₁₂₃₆ allele is a good, independent prognostic factor and the presence of this allele decreases the risk of death in comparison with a group without this allele (HR = 0.26; p = 0.0424). In addition, a statistically significant higher frequency of C₃₄₃₅ allele and significant differences in the C₃₄₃₅ allele distribution in N1/N2 group (91.7% and 62.5%, respectively) than N0 group (71.2% and 44.9%, respectively) was found. Each of the eight possible haplotypes was noted in M0 or I/II group and only seven in M1 or III/IV group. Haplotype T₁₂₃₆-G₂₆₇₇-C₃₄₃₅ only in less advanced CRC subjects (9.6% in I/II and 9.2% in M0 group) was detected. In addition, significant differences in haplotype distributions between M0 or I/II and M1 or III/IV group were found (p = 0.01 and p = 0.05, respectively).

Conclusions

These results suggest association between T₁₂₃₆ allele and T₁₂₃₆-G₂₆₇₇-C₃₄₃₅ haplotype and less advanced CRC, so these genetic markers may play a role as potentially good prognostic factors. Differences in haplotype distributions and degree of clinical staging may suggest that some other potential SNPs, especially in regulatory region of ABCB1/MDR1 gene, may influence P-glycoprotein function and CRC progression.

Gill S, Sinicrope FA (2005) Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Semin Oncol 32:24–34CrossRefPubMed

Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, Allemani C, Ciccolallo L, Santaquilani M, Berrino F, EUROCARE Working Group (2003) EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 14(Suppl 5):v128–149CrossRefPubMed

Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67–113CrossRefPubMed

Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–398CrossRefPubMed

Gottesman MM, Pastan I, Ambudkar SV (1996) P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6:610–617CrossRefPubMed

Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13–33CrossRefPubMed

Sakaeda T, Nakamura T, Okumura K (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:397–410CrossRefPubMed

Tanigawara Y (2000) Role of P-glycoprotein in drug disposition. Ther Drug Monit 22:137–140CrossRefPubMed

Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A (1996) Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48:1083–1089PubMed

10.

Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumour cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95:7024–7029CrossRefPubMed

11.

Randolph GJ, Beaulieu S, Pope M, Sugawara I, Hoffman L, Steinman RM, Muller WA (1998) A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc Natl Acad Sci USA 95:6924–6929CrossRefPubMed

12.

Mochida Y, Taguchi K, Taniguchi S, Tsuneyoshi M, Kuwano H, Tsuzuki T, Kuwano M, Wada M (2003) The role of P-glycoprotein in intestinal tumourigenesis: disruption of mdr1a suppresses polyp formation in Apc(Min/+) mice. Carcinogenesis 24:1219–1224CrossRefPubMed

13.

Kankesan J, Vanama R, Yusuf A, Thiessen JJ, Ling V, Rao PM, Rajalakshmi S, Sarma DS (2004) Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats. Carcinogenesis 25:425–430CrossRefPubMed

14.

Kankesan J, Yusuf A, Laconi E, Vanama R, Bradley G, Thiessen JJ, Ling V, Rao PM, Rajalakshmi S, Sarma DS (2003) Effect of PSC 833, an inhibitor of P-glycoprotein, on 1, 2-dimethylhydrazine-induced liver carcinogenesis in rats. Carcinogenesis 24:1977–1984CrossRefPubMed

15.

Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumours and tissues. Proc Natl Acad Sci USA 84:265–269CrossRefPubMed

16.

Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB (1991) Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumour aggressiveness and lymph node metastasis. Cancer Res 51:2720–2726PubMed

17.

Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, Hirohashi S (2000) Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 60:4761–4766PubMed

18.

Chin KV, Ueda K, Pastan I, Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459–442CrossRefPubMed

19.

Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878PubMed

20.

Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG, Pharmacogenetics of Membrane Transporters Investigators (2003) Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481–494CrossRefPubMed

21.

Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–174CrossRefPubMed

22.

Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG (2002) Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12:437–450CrossRefPubMed

23.

Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, Rothenpieler U, Kerb R, Hoffmeyer S, Brauch H (2002) Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumours. J Am Soc Nephrol 13:1847–1854CrossRefPubMed

24.

Jamroziak K, Młynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, Robak T (2004) Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 72:314–321CrossRefPubMed

25.

De Iudicibus S, De Pellegrin A, Stocco G, Bartoli F, Bussani R, Decorti G (2008) ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer. Anticancer Res 28:3921–3928PubMed

26.

Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, Koyama T, Okamura N, Miki I, Tamura T, Aoyama N, Kasuga M, Okumura K (2006) MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 21:126–132CrossRefPubMed

27.

Koyama T, Nakamura T, Komoto C, Sakaeda T, Taniguchi M, Okamura N, Tamura T, Aoyama N, Kamigaki T, Kuroda Y, Kasuga M, Kadoyama K, Okumura K (2006) MDR1 T-129C polymorphism can be predictive of differentiation, and thereby prognosis of colorectal adenocarcinomas in Japanese. Biol Pharm Bull 29:1449–1453CrossRefPubMed

28.

Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Bialecka M, Gornik W, Lubinski J (2005) Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 61:389–394CrossRefPubMed

29.

Potocnik U, Ravnik-Glavac M, Golouh R, Glavac D (2002) Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers. J Med Genet 39:340–346CrossRefPubMed

30.

Ho GT, Moodie FM, Satsangi J (2003) Multidrug resistance 1 gene (Pglycoprotein 170): an important determinant in gastrointestinal disease? Gut 52:759–766CrossRefPubMed

31.

Jass JR, Love SB, Northover JM (1987) A new prognostic classification of rectal cancer. Lancet 6:1303–1306CrossRef

32.

Panczyk M, Balcerczak E, Piaskowski S, Jamroziak K, Pasz-Walczak G, Mirowski M (2009) ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. Int J Colorectal Dis 24:895–905CrossRefPubMed

33.

Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143PubMed

34.

Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989CrossRefPubMed

35.

Kemp Z, Thirlwell C, Sieber O, Silver A, Tomlinson I (2004) An update on the genetics of colorectal cancer. Hum Mol Genet 13:R177–185CrossRefPubMed

36.

Gaikovitch E, Mrozikievicz P, Wagner F, Roots I (2004) Association of C3435T and G2677T/A polymorphisms of multidrug resistance gene with colorectal cancer risk. Clin Pharmacol Ther 75:17CrossRef

37.

Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD (1997) Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 36:11169–11178CrossRefPubMed

38.

Johnstone RW, Cretney E, Smyth MJ (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93:1075–1085PubMed

39.

Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrezou JP (1998) Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J 12:101–109PubMed

40.

Pallis M, Russell N (2000) P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 95:2897–2904PubMed

41.

Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD (2003) Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 6:71–84CrossRefPubMed

42.

Shen LX, Basilion JP, Stanton VP Jr (1999) Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci U S A 96:7871–7876CrossRefPubMed

43.

Frittitta L, Ercolino T, Bozzali M, Argiolas A, Graci S, Santagati MG, Spampinato D, Di Paola R, Cisternino C, Tassi V, Vigneri R, Pizzuti A, Trischitta V (2001) A cluster of three single nucleotide polymorphisms in the 3′-untranslated region of human glycoprotein PC-1 gene stabilizes PC-1 mRNA and is associated with increased PC-1 protein content and insulin resistance-related abnormalities. Diabetes 50:1952–1955CrossRefPubMed

44.

Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315:525–528CrossRefPubMed

45.

Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, Buclin T, Goldstein D, Decosterd L, Telenti A, Swiss HIV Cohort Study (2005) Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics 15:599–608CrossRefPubMed

46.

Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreeff M, Huber H (1996) Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 88:1747–1754PubMed

47.

van den Heuvel-Eibrink MM, Sonneveld P, Pieters R (2000) The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 38:94–110PubMed

48.

Gsur A, Zöchbauer S, Götzl M, Kyrle PA, Lechner K, Pirker R (1993) MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update. Leuk Lymphoma 12:91–94CrossRefPubMed

49.

Taniguchi S, Mochida Y, Uchiumi T, Tahira T, Hayashi K, Takagi K, Shimada M, Maehara Y, Kuwano H, Kono S, Nakano H, Kuwano M, Wada M (2003) Genetic polymorphism at the 5′ regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol Cancer Ther 2:1351–1359PubMed

50.

Rund D, Azar I, Shperling O (1999) A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. Adv Exp Med Biol 457:71–75PubMed

Title: ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer
Authors: Ewa Balcerczak
Mariusz Panczyk
Sylwester Piaskowski
Grażyna Pasz-Walczak
Aleksandra Sałagacka
Marek Mirowski
Publication date: 01-10-2010
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 10/2010
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-010-0961-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer

Abstract

Objective

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2010

Adiponectin and resistin: biomarker for colorectal cancer?

Single-incision laparoscopic low anterior resection for rectal cancer

Erratum to: Transcutaneous electrical posterior tibial nerve stimulation for faecal incontinence: effects on symptoms and quality of life

Primary clear cell adenocarcinoma of the rectum: a case report

Invited commentary on “Yun HR, Kim HC, Kim SH et al. (2010) Cytokeratin staining for complete remission in rectal cancer after chemoradiation. Int J Colorect Dis

Prognostic significance of AEG-1 expression in colorectal carcinoma